Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02833610 | A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency | PHASE2 | COMPLETED | 55 | — | — | Aug 1, 2016 | Mar 20, 2023 | Feb 18, 2026 | 7 | United States |
| Arm | Type | Description |
|---|---|---|
| Denosumab Injection | EXPERIMENTAL | Patients will be administered Denosumab Q4W at a pre-determine dose for 12 cycles. Denosumab Q4W is administered by subcutaneous injection. |
| Name | Type | Description |
|---|---|---|
| Denosumab Q4W | DRUG | - |
Inclusion Criteria: * Patients with symptomatic MM as defined by IMWG requiring anti-myeloma therapy. * Monoclonal plasma cells in the bone marrow greater than or equal to 10% and/or presence of a biopsy-proven plasmacytoma * Monoclonal protein present in the serum and/or urine * Creatinine cl...